365 related articles for article (PubMed ID: 9407968)
1. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene.
Böttinger EP; Jakubczak JL; Haines DC; Bagnall K; Wakefield LM
Cancer Res; 1997 Dec; 57(24):5564-70. PubMed ID: 9407968
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-beta signaling helps specify tumor type in DMBA and hormone-induced mammary cancers.
Crowley MR; Frost A; Chen DT; Baffi MO; Nicola T; Serra R
Differentiation; 2006 Feb; 74(1):40-52. PubMed ID: 16466399
[TBL] [Abstract][Full Text] [Related]
3. Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice.
Gorska AE; Joseph H; Derynck R; Moses HL; Serra R
Cell Growth Differ; 1998 Mar; 9(3):229-38. PubMed ID: 9543389
[TBL] [Abstract][Full Text] [Related]
4. A transgenic mouse model for mammary carcinogenesis.
Li B; Murphy KL; Laucirica R; Kittrell F; Medina D; Rosen JM
Oncogene; 1998 Feb; 16(8):997-1007. PubMed ID: 9519874
[TBL] [Abstract][Full Text] [Related]
5. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
Forrester E; Chytil A; Bierie B; Aakre M; Gorska AE; Sharif-Afshar AR; Muller WJ; Moses HL
Cancer Res; 2005 Mar; 65(6):2296-302. PubMed ID: 15781643
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
[TBL] [Abstract][Full Text] [Related]
7. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice.
Yamazaki M; Akahane T; Buck T; Yoshiji H; Gomez DE; Schoeffner DJ; Okajima E; Harris SR; Bunce OR; Thorgeirsson SS; Thorgeirsson UP
Carcinogenesis; 2004 Sep; 25(9):1735-46. PubMed ID: 15166086
[TBL] [Abstract][Full Text] [Related]
8. TGF beta regulation of cell proliferation.
Moses HL; Arteaga CL; Alexandrow MG; Dagnino L; Kawabata M; Pierce DF; Serra R
Princess Takamatsu Symp; 1994; 24():250-63. PubMed ID: 8983080
[TBL] [Abstract][Full Text] [Related]
9. Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development.
Amendt C; Schirmacher P; Weber H; Blessing M
Oncogene; 1998 Jul; 17(1):25-34. PubMed ID: 9671311
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the colony-stimulating factor (CSF-1) and/or its receptor c-fms in mammary glands of transgenic mice results in hyperplasia and tumor formation.
Kirma N; Luthra R; Jones J; Liu YG; Nair HB; Mandava U; Tekmal RR
Cancer Res; 2004 Jun; 64(12):4162-70. PubMed ID: 15205327
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice.
Murphy KL; Kittrell FS; Gay JP; Jäger R; Medina D; Rosen JM
Oncogene; 1999 Nov; 18(47):6597-604. PubMed ID: 10597264
[TBL] [Abstract][Full Text] [Related]
12. Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis.
Go C; Li P; Wang XJ
Cancer Res; 1999 Jun; 59(12):2861-8. PubMed ID: 10383147
[TBL] [Abstract][Full Text] [Related]
13. Expression of a dominant-negative mutant TGF-beta type II receptor in transgenic mice reveals essential roles for TGF-beta in regulation of growth and differentiation in the exocrine pancreas.
Böttinger EP; Jakubczak JL; Roberts IS; Mumy M; Hemmati P; Bagnall K; Merlino G; Wakefield LM
EMBO J; 1997 May; 16(10):2621-33. PubMed ID: 9184209
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL
Cancer Res; 2008 Mar; 68(6):1809-19. PubMed ID: 18339861
[TBL] [Abstract][Full Text] [Related]
15. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis.
Witty JP; Lempka T; Coffey RJ; Matrisian LM
Cancer Res; 1995 Apr; 55(7):1401-6. PubMed ID: 7882342
[TBL] [Abstract][Full Text] [Related]
16. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice.
Tomblyn S; Langenheim JF; Jacquemart IC; Holle E; Chen WY
Int J Oncol; 2005 Nov; 27(5):1381-9. PubMed ID: 16211235
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mice provide genetic evidence that transforming growth factor alpha promotes skin tumorigenesis via H-ras-dependent and H-ras-independent pathways.
Jhappan C; Takayama H; Dickson RB; Merlino G
Cell Growth Differ; 1994 Apr; 5(4):385-94. PubMed ID: 8043512
[TBL] [Abstract][Full Text] [Related]
18. Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7,12-dimethylbenzanthracene.
Coffey RJ; Meise KS; Matsui Y; Hogan BL; Dempsey PJ; Halter SA
Cancer Res; 1994 Apr; 54(7):1678-83. PubMed ID: 8137281
[TBL] [Abstract][Full Text] [Related]
19. Exposure of Sprague-Dawley rats to a 50-Hertz, 100-microTesla magnetic field for 27 weeks facilitates mammary tumorigenesis in the 7,12-dimethylbenz[a]-anthracene model of breast cancer.
Thun-Battersby S; Mevissen M; Löscher W
Cancer Res; 1999 Aug; 59(15):3627-33. PubMed ID: 10446973
[TBL] [Abstract][Full Text] [Related]
20. Mammary carcinogenesis in transgenic mice expressing a dominant-negative mutant of DNA polymerase beta in their mammary glands.
Wang L; Bhattacharyya N; Rabi T; Wang L; Banerjee S
Carcinogenesis; 2007 Jun; 28(6):1356-63. PubMed ID: 17166880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
